Cardonilmab for advanced melanoma or kidney cancer
Part of Cancer, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new drug called Cardonilmab for people with advanced melanoma or advanced kidney cancer that has not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old
- You have advanced melanoma (mucosal or acral type) or advanced kidney cancer that has progressed after at least two prior treatments, including a PD-1/PD-L1 drug
- You have at least one tumor that can be measured on a CT scan or MRI
- You are able to get out of bed and take care of yourself (ECOG score 0-2)
- Your major organs (like bone marrow, liver, kidneys, heart) are working well enough based on blood tests and heart scan
- You do not have untreated brain metastases, active autoimmune disease, uncontrolled infection, or other cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, cadonilimab and anlotinib, for people with melanoma that has gotten worse or spread after their first treatment. It aims to see if this new combination can help when standard options have stopped working.
This trial tests a combination of two drugs, Vorolanib and Cadonilimab, for people with advanced or metastatic clear cell kidney cancer who have not had prior treatment. It aims to see if the combination shrinks the cancer and how safe it is.
This trial tests a combination of two drugs (cadonilimab and interferon) given before surgery to treat advanced melanoma that has spread to nearby lymph nodes or one distant site. The goal is to shrink tumors and improve chances of successful surgery and long-term survival.
This trial tests a combination of an immunotherapy drug (Cardonizumab) and a targeted therapy pill (TKI) for people with advanced liver cancer whose prior treatment has stopped working. The goal is to see if this second-line combination can help shrink tumors or slow the disease.
This Phase 2 study tests whether combining anti–PD-1 treatment with aldesleukin can shrink or control metastatic melanoma or metastatic kidney (renal cell) cancer. It is mainly for people who have either not had anti–PD-1 before, or whose cancer did not respond to prior anti–PD-1 treatment.
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
Hear when a new Participants Who Had Received Second-line or Higher Advanced Melanoma and Advanced Renal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.